GLP1R and Mental deterioration: Although exploratory or post-hoc analyses of randomized trials [21, 22] suggest GLP1 receptor agonists versus placebo may protect against cognitive decline, complementary real-world evidence studies with rigorous methodology and sufficient events have been limited to three studies, [16, 23, 24] and the results are mixed.